The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

SARS-CoV-2 causes persistent infections in a subset of individuals, which is a major clinical
and public health problem that should be prioritised for further investigation for several …

Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …

Immunocompromised patients still experience unpredictable courses of COVID-19, despite
that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …

Another recent publication reported success with a combination of monoclonal antibodies, 7
days of remdesivir, and 5 days of nirmatrelvir/ritonavir [2]. Influenced by the report from …

Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir
combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and …

Background: Prolonged SARS-CoV-2 infections in immunocompromised hosts may predict
or source the emergence of highly mutated variants. The types of immunosuppression …

More than 3 years have passed since Coronavirus disease 2019 (COVID‐19) was declared
a global pandemic, yet COVID‐19 still severely impacts immunocompromised individuals …

Background Morbidity and mortality are higher in immunocompromised patients affected by
COVID-19 than in the general population. Some authors have successfully used antiviral …

Immunocompromised patients with B-cell deficiencies are at risk for prolonged symptomatic
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We describe 4 …